![]() |
|
|
Vol. 12, Issue 5, 1467-1479, May 2001

and
Departments of *Cellular and Molecular Medicine and
Pathology University of California, San Diego, La Jolla,
California 92093-0651
| |
ABSTRACT |
|---|
|
|
|---|
Low-density lipoprotein receptor-related protein (LRP) mediates internalization of urokinase:plasminogen activator inhibitor complexes (uPA:PAI-1) and the urokinase receptor (uPAR). Here we investigated whether direct interaction between uPAR, a glycosyl-phosphatidylinositol-anchored protein, and LRP, a transmembrane receptor, is required for clearance of uPA:PAI-1, regeneration of unoccupied uPAR, activation of plasminogen, and the ability of HT1080 cells to invade extracellular matrix. We found that in the absence of uPA:PAI-1, uPAR is randomly distributed along the plasma membrane, whereas uPA:PAI-1 promotes formation of uPAR-LRP complexes and initiates redistribution of occupied uPAR to clathrin-coated pits. uPAR-LRP complexes are endocytosed via clathrin-coated vesicles and traffic together to early endosomes (EE) because they can be coimmunoprecipitated from immunoisolated EE, and internalization is blocked by depletion of intracellular K+. Direct binding of domain 3 (D3) of uPAR to LRP is required for clearance of uPA-PAI-1-occupied uPAR because internalization is blocked by incubation with recombinant D3. Moreover, uPA-dependent plasmin generation and the ability of HT1080 cells to migrate through Matrigel-coated invasion chambers are also inhibited in the presence of D3. These results demonstrate that GPI-anchored uPAR is endocytosed by piggybacking on LRP and that direct binding of occupied uPAR to LRP is essential for internalization of occupied uPAR, regeneration of unoccupied uPAR, plasmin generation, and invasion and migration through extracellular matrix.
| |
INTRODUCTION |
|---|
|
|
|---|
The urokinase plasminogen activator (uPA):plasmin system is
involved in enhancing cell migration and invasion (Cohen et
al., 1991
; Reiter et al., 1993
) during embryogenesis,
wound healing, and metastasis (reviewed by Andreasen et al.,
1994
; Dano et al., 1985
). Our current
understanding of the uPA system is that uPA is activated upon binding
to its cell surface receptor, uPAR (Cubellis et al.,
1989
;), a glycosyl-phosphatidylinositol (GPI)-anchored membrane protein (Nielsen et al., 1988
; Ploug
et al., 1991
) with three homologous extracellular
domains (D1, 2, and 3) (Behrendt et al., 1991
). After
activation, uPA catalyzes the conversion of plasminogen to plasmin
(Ellis et al., 1989
), which has a broad substrate
specificity and is able to degrade many extracellular matrix proteins
(Moser et al., 1993
). uPA-dependent plasminogen activation is inhibited by specific uPA inhibitors with the best studied being plasminogen activator inhibitor type-1 (PAI-1) (Blasi et al., 1987
; Saksela and Rifkin, 1988
).
Inactive uPA:PAI-1 complexes are rapidly internalized by the LDL
receptor-related protein (LRP) (Herz et al., 1988
, 1992
) and
degraded in lysosomes (Olson et al., 1992
; Conese et
al., 1995
). Clearance of uPA:PAI-1 by LRP is accompanied by
decreased uPAR at the cell surface, suggesting that uPAR is also
internalized by LRP (Herz et al., 1992
; Olson et
al., 1992
; Williams et al., 1994
; Conese et
al., 1995
). It has also been demonstrated that when binding of
uPA:PAI-1 to LRP is prevented with antibodies against LRP, cell surface
plasminogen activity is reduced, presumably by delaying internalization
of uPAR and preventing regeneration of unoccupied uPAR capable of binding uPA (Zhang et al., 1998
).
Although this is the widely accepted model for regulation of the uPA system, the detailed mechanisms of how uPAR and LRP cooperate in clearance of uPA:PAI-1 as well as the trafficking itinerary of uPAR are not well understood. For example, it is not clear whether uPAR directly interacts with LRP or whether uPA-PAI-1 bridges uPAR and LRP. Moreover, the pathway by which uPAR is internalized has not yet been established.
LRP, like other members of the LDL receptor family, is internalized via
clathrin-coated pits (Herz et al., 1988
; Chen et
al., 1990
; Krieger and Herz, 1994
), whereas uPAR, a GPI-anchored
protein, has been shown to be distributed randomly along the plasma
membrane (PM) under steady-state conditions (Conese et
al., 1995
; Maxfield and Mayor, 1997
; Nykjaer et al.,
1997
).
To achieve a better understanding of the interplay between uPAR and LRP in regulation of cell surface plasminogen activator activity, we have investigated the interaction between uPAR and LRP and the trafficking of uPAR and LRP in HT1080 cells, a human fibrosarcoma cell line. We demonstrate here that uPA:PAI-1 initiates direct binding of domain 3 (D3) of uPAR to LRP on the PM and redistribution of uPAR to clathrin-coated pits and that this interaction is necessary for cointernalization of the two receptors into early endosomes (EE). We also show that binding of uPAR to LRP is essential for clearance of uPA:PAI, regeneration of unoccupied uPAR, and plasmin generation at the cell surface.
| |
MATERIALS AND METHODS |
|---|
|
|
|---|
Reagents
Human two-chain-uPA was purchased from American Diagnostica (Greenwich, CT) and human PAI-1 from Calbiochem (San Diego, CA). Holo-transferrin (Tf) and CHAPS were obtained from Sigma (St. Louis, MO), protein G-agarose from Amersham Pharmacia Biotech (Piscataway, NJ), and the thiol cleavable cross-linker 3,3'-dithiobis [sulfo succinimidyl-propionate] (DTSSP) from Pierce (Rockford, IL). Chromozym PL was purchased from Roche Molecular Biochemicals (Indianapolis, IN).
Antibodies
Mouse mAb against human uPAR was provided by Dr. Marc Shuman
(University of California, San Francisco). A rabbit polyclonal antibody
against recombinant soluble human uPAR1-274 (465)
was generated as previously described (Orlando and Farquhar, 1993
). Anti-LRP (456) was raised in rabbits against human LRP (Orlando and
Farquhar, 1994
), and anti-LRP (1073) was raised against a 14 amino acid
peptide from the cytoplasmic tail of human LRP (Czekay et
al., 1995
). Mouse mAb against the ectodomain of human LRP (8G1) was obtained from Dr. Dudley Strickland (Holland Laboratory, American Red Cross, Rockville, MD). A hybridoma cell line expressing mAb 11H4
(recognizes the cytoplasmic tail of human LRP) was obtained from
American Type Culture Collection. Polyclonal antisera against the
cytoplasmic tail of human transferrin (TF) receptor and human uPA were
obtained from Dr. Ian Trowbridge (Salk Institute) and Oncogene
(Cambridge, MA), respectively. Affinity-purified chicken polyclonal
antibodies against a peptide from the N terminus of human
caveolin-1 (Stan et al., 1997
) were provided by Dr. Radu V. Stan (University of California, San Diego). Affinity-purified mAb
against AP-2
-adaptin (Beck et al., 1992
) was provided by Dr. Sandra Schmid (Scripps Research Institute). HRP-coupled
donkey anti-rabbit or anti-mouse (H+L) IgG, depleted of
cross-reactivity, was purchased from Jackson ImmunoResearch
Laboratories (West Grove, PA).
Cell Culture
Normal rat kidney (NRK) cells and human fibrosarcoma HT1080 cells were purchased from American Type Culture Collection and cultured according to their instructions. Cells were grown to confluency over 3-6 d.
Expression and Purification of Recombinant Soluble uPAR and Domains 2 and 3 of Human uPAR
uPAR cDNA (IMAGE Consortium, accession number T75241) encoding
amino acids 1-274 (lacking the GPI-anchor site), D2 (encoding amino
acids 92-174), and D3 cDNAs (encoding amino acids 192-274) were
amplified by PCR (primers available on request) and subcloned into
pET28b (EcoRI/HindIII; Novagen, Madison, WI).
Escherichia coli strain BL21-DE3 expressing soluble
uPAR1-274 and the D2 and D3 domains of uPAR were
grown and induced as described (Orlando and Farquhar, 1994
). Bacteria
were pelleted by centrifugation (2500 × g, 10 min,
4°C), resuspended in TBS (20 mM Tris, pH 7.4, 150 mM NaCl) containing
100 µg/ml lysozyme, and lysed in TBS containing 3%
N-lauroyl sarcosine. Lysates were cleared by centrifugation (15,000 × g, 20 min, 4°C), and supernatants were
incubated with Ni2+-affinity resin (ProBond;
Invitrogen, Carlsbad, CA). Bound uPAR1-274, D2,
and D3 were eluted with TBS, 0.1% N-lauroyl sarcosine, 500 mM imidazole, and dialyzed against TBS, 0.1% N-lauroyl sarcosine.
Immunofluorescence
For immunofluorescence cells were grown to ~75% confluence on
glass coverslips, fixed for 20 min with 2% formaldehyde in 0.1 M
phosphate buffer, pH 7.4, quenched in PBS containing 0.1% BSA and 10 mM glycine for 30 min as described (McCaffery and Farquhar, 1995
), and
permeabilized with 0.05% Triton X-100 in PBS for 3 min. Cells were
then incubated with primary rabbit, mouse, or chicken antibodies for
1 h followed by incubation with appropriate Alexa 594- or Alexa
488-conjugated goat anti-rabbit, anti-mouse, or anti-chicken IgG
(Molecular Probes, Eugene, OR). In some cases anti-uPAR antibodies were
bound to the surface at 4°C in the presence or absence of D3 before
fixation (Myohanen et al., 1993
). Cells were examined by
deconvolution microscopy with the Applied Precision DeltaVision imaging
system coupled to an inverted Nikon SE 200 fluorescence
microscope. For cross-sectional images of cells, stacks of at least 50 sections (150-nm step width) of raw image data were obtained to
optimize reconstruction of the center plane image. Deconvolution was
done on a SGI workstation (UNIX) using DeltaVision reconstruction
software, and images were processed as TIFF files, pseudocolored, and
superimposed using Photoshop 5.0 (Adobe Systems, Mountain View, CA).
Immunoblotting and Immunoprecipitation
For immunoblotting, cell lysates were prepared
in 10 mM CHAPS in buffer A (20 mM HEPES, pH 7.4, 150 mM NaCl, 2 mM
CaCl2) and processed for SDS-PAGE (Laemmli,
1970
), immunoblotting, and detection by enhanced
chemiluminescence (Pierce) as described (Czekay et al.,
1997
). Biotinylated proteins were detected using HRP-avidin (ABC-Biotinylation kit; Vector Laboratories, Burlingame, CA).
For immunoprecipitation, cell lysates were incubated with mAbs against either uPAR (3.9 µg) or LRP (2.6 µg), mixed with protein G-agarose beads (20 µl/1 ml of cell lysate) for 16 h at 4°C, and processed for SDS-PAGE, followed by autoradiography or immunoblotting and densitometry.
Radioiodination
Holo Tf,
2M, uPAR1-274, and D3 were
radioiodinated with Na-125I (PerkinElmer Life
Science Products, Boston, MA) using Iodo-Beads (Pierce).
Specific activities were 4994, 1861, 3550, and 9821 cpm/ng,
respectively. Cell surface proteins were radioiodinated using the
lactoperoxidase method (Czekay et al., 1995
).
Purification, Activation, and Degradation of
2M
2-Macroglobulin (
2M) was purified from pooled citrated
human plasma (San Diego Blood Bank, San Diego, CA) as described
(Kurecki et al., 1979
) except that elution buffer was
modified to 0.01 M Na-acetate and 0.15 M NaCl, pH 5. Purified
2M was
activated for receptor binding with 0.4 M methylamine in 0.1 M
Tris-HCl, pH 8, for 2 h at room temperature and unbound
methylamine removed by passage over a PD-10 column (Amersham Pharmacia Biotech).
Cells were incubated at 37°C with 125I-labeled
2M (2 nM) for 8 h in the presence or absence of unlabeled
2M
(40 nM) in DMEM, 1 mg/ml BSA, 10 mM HEPES, pH 7.4. Medium was removed
after 0, 2, 4, and 8 h, microfuged for 2 min, and supernatants
were processed for trichloroacetic acid (TCA) precipitation and gamma
counting (Czekay et al., 1997
). Degradation was calculated
as TCA-soluble cpm divided by specific activity of the radioiodinated
ligand (Czekay et al., 1997
) normalized to total cellular
protein (BCA Protein Assay; Pierce).
Cell Surface Biotinylation
Cell monolayers were acid-washed in isoosmolar buffer B (50 mM
glycine-HCl, pH 3.0, 100 mM NaCl) for 3 min at 4°C to release endogenous bound uPA from surface uPAR (Cubellis et al.,
1989
). After washing (twice in buffer B and twice in ice-cold PBS),
surface proteins were biotinylated with 400 µM Biotin-XX (Molecular
Probes) on ice for 35 min, and the reaction was quenched with 20 mM
glycine in PBS, pH 7.4, for 15 min.
Cell Surface Binding and Uptake of Radioiodinated Tf and
2M
Cells were incubated with 125I-labeled
holo-Tf (200 ng/ml) at 4°C (to radiolabel the cell surface pool of Tf
receptor) and 18°C (to allow uptake of
125I-labeled Tf into EE) (Czekay et
al., 1997
) after which the cells were acid-washed to release
125I-labeled Tf bound to Tf receptors at the cell
surface (Czekay et al., 1997
).
125I-labeled
2M (2 nM) was bound to cells for
4 h at 4°C in the presence or absence of varying amounts of
unlabeled
2M (0.06-40 nM), rinsed, and cell-associated
radioactivity was quantified by gamma counting and normalized to total
cellular protein (BCA Protein Assay; Pierce). Binding affinities
(apparent KD) for
125I-labeled
2M were determined as the
concentration of unlabeled
2M which resulted in 50% inhibition of
binding. Specificity was determined as the difference between total
binding (without competition) and nonspecific binding (noncompetable).
The amount of bound ligand was calculated as cpm divided by the
specific activity of 125I-labeled
2M.
Cross-linking Experiments
125I-labeled, recombinant uPAR1-274 (25 nM) was bound to HT1080 cells in serum-free DMEM (containing 2% BSA, 20 mM HEPES, pH 7.4) for 2 h at 4°C in the presence or absence of unlabeled recombinant uPAR1-274 (2.5 µM) or the D2 (1.25 µM) or D3 (1.25 µM) domains of uPAR. Cells were washed and bound proteins were cross-linked using the thiol cleavable cross-linker DTSSP (1 mM) (Pierce) for 20 min at 4°C. The reaction was quenched with TBS for 10 min at 4°C, cell lysates were prepared in 10 mM CHAPS, and immunoprecipitation was carried out with anti-LRP mAb (11H4).
Binding of 125I-uPAR1-274 or 125I-D3 to Purified LRP
Placental tissue (Scripps Clinic, La Jolla, CA) was finely minced, homogenized in buffer A (containing 10 µg/ml aprotinin, 0.5 mM PMSF) by using a TissueMizer (Tekmar, Cincinnati, OH) for 3 min, and centrifuged (15,300 × g, 30 min) at 4°C. Placental proteins were extracted with 10 mM CHAPS in buffer A for 2 h, and LRP was affinity purified on mAb 11H4 (5 mg) prebound to protein G-Sepharose beads (Oncogene). The bound material contained only LRP when analyzed by SDS-PAGE and silver staining.
Affinity-purified immobilized LRP was incubated with either
125I-uPAR1-274 (100 nM) or
125I-D3 (50 nM) in the presence or absence of
unlabeled uPAR1-274 (4 µM), D2 (1.5 µM), or
D3 (1.5 µM), and radioiodinated proteins were visualized by
autoradiography followed by densitometry or PhosphorImager analysis
(Czekay et al., 1995
).
Internalization of uPAR after Binding uPA:PAI-1 and Cell Fractionation
uPA:PAI complexes were formed by incubation of PAI-1 (5 µM)
with two-chain uPA (100 nM) for 1 h at room temperature as
described (Cubellis et al., 1989
). Cells were acid-washed,
biotinylated (to specifically label the surface pool of uPAR), and
incubated with uPA:PAI-1 (50 nM) for 1 h at 4°C or sequentially
at 4 and 18°C, 1 h each, and cell fractionation was carried out
as described (Czekay et al., 1997
). In brief, postnuclear
supernatants (1 ml) were top loaded onto isoosmolar 20%-Percoll
(Amersham Pharmacia Biotech, Alameda, CA), and gradients were
established by centrifugation (20,000 × g, 52 min) at
4°C. Fractions (1 ml) were collected from the top of the gradient,
and the distribution of biotinylated uPAR was determined by
immunoprecipitation with anti-uPAR mAb followed by blotting with
HRP-coupled avidin and detection by chemiluminescence. In some cases,
binding and internalization were done in the presence of either 200 µg/ml protein A-purified anti-LRP IgG (456), which blocks ligand
binding to LRP (Orlando, unpublished observations), or 2.5 µM D3 to
block uPAR binding to LRP. All solutions contained
Ca2+, which is required for ligand binding to LRP
(Moestrup et al., 1990
). For K+
depletion, cells were incubated in 5 ml of hypotonic medium (1:1, DMEM/water) before uPA:PAI-1 binding followed by incubation for 30 min
in isotonic K+-free buffer (Larkin et
al., 1983
) at room temperature.
Binding of 125I-uPA:PAI-1 to uPAR1-274
Recombinant purified human uPAR1-274 (2 nM) was incubated in PBS for 1 h at 4°C with 125I-uPA:PAI-1 (10 nM) complexes in the presence or absence of D3 (100 nM), and samples were mixed with anti-uPAR (465) and protein G-Sepharose beads (Oncogene) for 16 h at 4°C. Bound proteins were processed for SDS-PAGE, autoradiography, and densitometry.
Immunoisolation of Early Endosomes
Postnuclear supernatants were fractionated on Percoll gradients
as described above and gradient fractions 8-10 (containing EE) were
pooled. mAb 11H4, specific for the C terminus of human LRP, was
prebound to protein G-agarose beads in buffer B and subsequently incubated with pooled fractions 8-10 for 2 h at room temperature. After washing, immunoisolates were incubated for 1 h on ice in buffer B containing 10 mM CHAPS, beads were separated from
supernatant by centrifugation, and Percoll in the supernatant was
pelleted (Czekay et al., 1997
). Proteins released into the
supernatant and those remaining bound to the agarose beads were
processed for immunoblotting.
uPA Activity at the Cell Surface
Cells were acid-washed as described above, incubated with uPA:PAI-1 (10 nM) at 4°C for 1 h, and, after removing unbound ligand, at 37°C for 1 h in the presence or absence of D3 (5 µg/ml). Subsequently, active uPA (2 nM) was bound to HT1080 cells at 4°C for 1 h in the presence of anti-LRP (456), 200 µg/ml. After washing, cells were incubated in 50 mM Tris-HCl, pH 7.4, 0.1 M NaCl with 0.2 µM human plasminogen (Calbiochem) and 0.5 mM Chromozym PL (Tosyl-Gly-ProLys-4-nitranilide-acetate; Roche Molecular Biochemicals), a chromogenic substrate for plasmin, according to the manufacturer's instructions. Hydrolysis of the substrate was measured at 405 nm, and absorbance was used to calculate the generation of plasmin (U/ml).
Transwell Invasion Assays
Cells were detached from tissue culture plates with PBS, pH 7.4, containing 10 mM EDTA, and resuspended in DMEM (10% fetal calf serum). Cells (5 × 105/500 µl) were added to the upper compartment of Matrigel-coated invasion chambers, 8-µm pore size (Becton Dickinson, Bedford, MA) in the presence or absence of soluble uPAR1-274 (2.5 µM), D3 (1.25 µM), or D3 and active uPA (8 nM). Culture medium alone (750 µl) was added to the lower part of the invasion chamber. After incubation at 37°C for 36 h, cells were removed from the upper side of the filter membrane by using cotton swabs. Filters were fixed, stained, and mounted according to the manufacturer's instructions. Cells that invaded through the Matrigel and migrated to the under side of the filter were counted. The values obtained were calculated by averaging the total number of cells from three filters per condition.
| |
RESULTS |
|---|
|
|
|---|
LRP Expressed on the Surface of HT1080 Cells Is Functionally Active
To study the interactions between uPAR and LRP we used HT1080
cells, a human fibrosarcoma cell line, known to express functional uPAR
on the PM (Xue et al., 1997
). Because LRP expression has not
been previously studied in this cell line, we first verified that it is
expressed and functionally active at the cell surface. LRP was clearly
detected after cell surface radioiodination of HT1080 cells followed by
immunoprecipitation with anti-LRP mAb (11H4), and it
comigrated with LRP from NRK cells (Herz et al., 1990
)
(Figure 1A, inset). We then tested
whether HT1080 cells are capable of binding and internalizing
2M, a
well-established specific ligand for LRP.
125I-labeled
2M bound to HT1080 cells with an
apparent KD of 0.75 nM (Figure 1A),
and 42 ng of 125I-labeled
2M/mg of total cell
protein was degraded in a linear manner over 8 h (Figure 1B).
Thus, the ability of HT1080 cells to bind and degrade ligand is
comparable to noncancer cells (Moestrup and Gliemann, 1989
).
|
LRP Is Located in Clathrin-coated Pits on the Plasma Membrane of HT1080 Cells
Next, we investigated the distribution of LRP on the PM of HT1080
cells under steady-state conditions by immunofluorescence. Because it
has been assumed that LRP is localized in clathrin-coated pits (Herz
et al., 1988
; Krieger and Herz, 1994
), we carried out double
labeling for LRP and AP-2, a well-established marker for clathrin-coated pits and vesicles associated with the PM (Brodsky, 1997
). Staining for LRP (Figure 2A) was
concentrated along the PM where it showed a striking overlap with AP-2
(Figure 2B), confirming its location in clathrin-coated pits.
|
Distribution of uPAR on the Plasma Membrane of HT1080 Cells
To determine the distribution of uPAR we carried out double
labeling for uPAR and either AP-2 or caveolin-1, a marker for caveolae
(Rothberg et al., 1992
). Staining for uPAR (Figure 2, D and
G), caveolin-1 (Figure 2E), and AP-2 (Figure 2H) was seen on the PM,
but there was little or no overlap between uPAR and either caveolin or
AP-2. We conclude that under steady-state conditions LRP is associated
with clathrin-coated pits, whereas uPAR is not associated with either
clathrin-coated pits or caveolin-enriched microdomains.
Redistribution of uPAR on the PM in the Presence of uPA:PAI-1 Complexes
Binding of exogenous uPA:PAI-1 complexes to uPAR has been
shown to initiate internalization of both uPA:PAI-1 and uPAR (Olson et al., 1992
). To investigate the fate of uPAR after
uPA:PAI-1 binding we carried out immunofluorescence on HT1080 cells
that had been acid-washed to release endogenous bound ligand followed by incubation in the presence or absence of uPA:PAI-1 complexes at
4°C, and double labeling for uPAR and LRP. We found that in the
absence of uPA:PAI-1, there was little overlap in staining for uPAR and
LRP (Figure 3, A-C). However, in the
presence of uPA:PAI-1, the overlap in staining for uPAR with both LRP
(Figure 3, D-F) and AP-2 (Figure 3, G-I) was strikingly increased.
These data indicate that binding of uPA:PAI-1 to uPAR induces
redistribution of occupied uPAR on the PM to clathrin-coated pits,
suggesting that uPA:PAI-1 may bridge uPAR and LRP.
|
uPAR Coprecipitates with LRP after uPA:PAI-1 Binding to the Cell Surface
To find out whether uPAR and LRP form a molecular complex after
binding uPA and PAI-1, we carried out immunoprecipitation with anti-LRP
mAb (11H4) on lysates of HT1080 cells incubated at 4°C in the
presence or absence of uPA:PAI-1 followed by
immunoblotting for uPAR. We found considerable uPAR in
precipitates obtained with anti-LRP from cells incubated in the
presence of uPA:PAI-1 (Figure 4, lane 2),
whereas only traces of uPAR could be detected in precipitates from
controls incubated in the absence of uPA:PAI-1 (Figure 4, lane 1).
These data indicate that LRP and uPAR form immunoprecipitable complexes
at the surface of HT1080 cells in the presence of uPA:PAI-1.
|
Coimmunoprecipitation of uPAR1-274 with Endogenous LRP
Next, we tested whether uPAR binds to endogenous LRP on the PM by
carrying out cross-linking experiments in the presence of recombinant,
soluble (lacking a GPI-anchor) uPAR. When
125I-uPAR1-274 was bound to
the cell surface of acid-washed cells at 4°C followed by
cross-linking and immunoprecipitation with anti-LRP mAb (11H4),
considerable 125I-uPAR1-274
coprecipitated with LRP (Figure 5A, lane
2). The amount of 125I-uPAR that coprecipitated
was greatly reduced (>85%) in the presence of unlabeled
uPAR1-274 (Figure 5A, lane 3). When similar
experiments were carried out in the presence of recombinant D3 or D2,
D3 greatly reduced (>90%) uPAR1-274 binding
(Figure 5A, lane 5), whereas D2 had no significant effect (Figure 5A,
lane 4). These findings suggest that uPAR binds to LRP through D3.
|
uPAR1-274 Binds Directly to Affinity-purified LRP through Domain 3
Next, we incubated affinity-purified, immobilized LRP with 125I-uPAR1-274 in the presence or absence of unlabeled uPAR1-274, D2, or D3. We found that 125I-uPAR1-274 bound directly to LRP (Figure 5B, lane 1), and the amount bound was greatly reduced (>85%) in the presence of unlabeled uPAR1-274 (Figure 5B, lane 2) or D3 (Figure 5B, lane 4). D2 had no effect on the binding (Figure 5B, lane 3). Furthermore, we found that 125I-D3 also bound to immobilized LRP (Figure 5B, lane 5), and binding was reduced (>90%) in the presence of unlabeled D3. Collectively, these results demonstrate that 1) uPAR binds directly to LRP on the surface of HT1080 cells, and 2) the binding site is located in D3.
uPAR with Bound uPA:PAI-1 and LRP Are Internalized and Delivered to Early Endosomes
To investigate the trafficking of uPAR:LRP complexes in the
presence of uPA:PAI-1, we carried out subcellular fractionation by
using 125I-Tf as a marker to identify PM and EE
fractions. When HT1080 cells were incubated with
125I-Tf for 1 h at 4°C and homogenates
were fractionated on isoosmotic Percoll gradients, the majority of the
125I-Tf sedimented in gradient fractions 4-6
(Figure 6A, open squares), indicating the
location of PM. After incubation of cells at 18°C for 1 h to
allow uptake into EE, the majority of the 125I-Tf
sedimented in fractions 8-10 (Figure 6A, closed squares), defining
fractions containing EE.
|
To follow the fate of uPAR after uPA:PAI-1 binding, HT1080 cells
were surfaced biotinylated, incubated with uPA:PAI-1, and fractionated
on Percoll gradients after incubation at 4°C or binding at 4°C
followed by incubation at 18°C for 1 h. After uPA-PAI-1 binding
at 4°C, the majority of the biotinylated uPAR cosedimented with
125I-Tf in PM fractions (4-6) (Figure 6B).
However, when cells were subsequently incubated at 18°C after binding
the peak of the biotinylated uPAR shifted to EE fractions (8-10)
(Figure 6C). When similar experiments were carried out on cells
incubated in the presence of anti-LRP (456) (Figure 6E) at 18°C, uPAR
remained largely associated with PM-containing fractions, confirming
previous reports that anti-LRP blocks internalization of uPAR (Zhang
et al., 1998
). From these results we conclude that uPAR is
internalized into an EE compartment after uPA:PAI-1 binding, and
internalization occurs via LRP.
uPAR Is Internalized via Clathrin-coated Vesicles
LRP is known to be internalized via clathrin-coated vesicles (Chen
et al., 1990
), but the route of internalization of uPAR has
not yet been established. To obtain information on this point we used a
procedure (i.e., hypotonic shock and depletion of intracellular K+) that selectively blocks clathrin-mediated
endocytosis (Larkin et al., 1983
) but has no effect on
internalization via caveolae (Roettger et al., 1995
). When
cells were K+ depleted and incubated at 18°C as
described above, uptake of both 125I-Tf (Figure
6A, open triangles) and uPAR (Figure 6D) was completely abolished.
These results together with our immunocytochemical data demonstrate
that internalization of occupied uPAR is clathrin mediated.
D3 Blocks Internalization of uPAR but Does Not Affect Binding of uPAR:PAI-1
Next, we tested the effects of D3 on internalization of uPAR. We found that internalization of uPAR was blocked in the presence of D3, because uPAR remained largely associated with PM-containing fractions (Figure 6F).
Because previous studies have suggested that regions within D3 are
important for high-affinity binding of uPA to uPAR (Ploug, 1998
), it
was necessary to determine whether D3 blocks binding of uPA:PAI-1 to
uPAR. Thus, we carried out experiments in which we incubated
125I-uPA:PAI-1 complexes (10 nM) with recombinant
purified human uPAR1-274 (2 nM) in the presence
or absence of D3 (100 nM). We found that D3 had no effect on the
binding of uPA:PAI-1 to uPAR1-274 (Figure 5C).
We also found that D3 does not block redistribution of uPAR induced by uPA:PAI-1 complexes (Figure 3, J-L). We conclude that D3 blocks internalization of uPAR but has no affect on the binding of uPA:PAI-1 to uPAR or on the redistribution of uPAR with bound uPA:PAI-1 to clathrin-coated pits.
Presence of uPAR:LRP Complexes in Early Endosomes
Next, we investigated whether uPAR and LRP remain associated
during internalization into EE. We prepared EE fractions (8-10) from
surface biotinylated cells incubated at 18°C in the presence of
uPA:PAI-1 and used them as starting material for immunoisolation of EE
on mAb 11H4 (specific for the cytoplasmic tail of LRP), which had been
prebound to protein G-agarose. Vesicles that had been immunoadsorbed to
the beads were then detergent solubilized (to release
non-LRP-associated proteins), and the beads with bound LRP were
pelleted and analyzed by immunoblotting for
LRP-associated proteins. As shown in Figure
7, most (>90%) of the uPA:PAI-1 (lane 3) and Tf receptor (lane 4) were released into the supernatant after
detergent treatment, whereas most (>90%) of the LRP (lane 5) and uPAR
(lane 6) remained bound to the beads. These results show that uPAR and
LRP are internalized together and remain associated in EE, whereas most
of the uPA:PAI-1 is no longer bound to uPAR in EE.
|
D3 Blocks Cell Surface uPA Activity
Previously, it was shown that blocking uPA:PAI-1 binding to LRP
with RAP impairs regeneration of unoccupied uPAR and reduces uPA
activity at the cell surface, presumably by blocking endocytosis of
uPAR (Zhang et al., 1998
). Thus, we reasoned that blocking uPAR binding to LRP should also lead to decreased cell surface uPA
activity and subsequent generation of plasmin in HT1080 cells. To
determine whether this is the case we quantified uPA-dependent plasmin
activation in the presence and absence of D3 using a chromagenic assay.
After incubation with uPA:PAI-1 in the presence of recombinant D3 at
4°C (1 h) or 37°C (1 h), there was a ~60% reduction in
surface-bound uPA activity (0.5 ± 0.02 mU/ml plasmin activity)
compared with controls (1.5 ± 0.1 mU/ml) over 60 min (Figure
8). These results suggest that preventing
the binding of uPAR to LRP with recombinant D3 results in decreased uPA
activity at the cell surface, presumably by preventing clearance of
occupied uPAR and regeneration of unoccupied uPAR capable of binding
activated uPA at the cell surface.
|
D3 Inhibits Migration of HT1080 Cells through Matrigel-coated Transwell Chambers
Because blocking LRP:uPAR interaction reduces cell surface uPA
activity it might also be expected to slow or prevent the ability of
cells to migrate through the extracellular matrix. To determine whether
this is the case, we carried out a well-established cell invasion assay
(Kramer et al., 1986
; Albini et al., 1987
; Chen et al., 1997
) in which we analyzed the ability of HT1080
cells to migrate through Matrigel-coated Transwell invasion chambers in
the presence or absence of soluble uPAR1-274 or
D3. In the absence of uPAR1-274 or D3 (Figure
9) 115 (± 12) cells (100%) migrated
through the Matrigel layer. However, in the presence of recombinant
uPAR1-274 or D3 the number of cells that migrated through the filter was reduced to 54 (± 3) cells (47%) and 9 (± 3)
cells (8%), respectively. Addition of proteolytically active uPA to
cells incubated in the presence of D3 restored the number of HT1080
cells able to migrate through the Matrigel-coated filters to control
levels (105 [± 7] cells; 91%), indicating that the effect can be
attributed in large part to uPA. No significant affect on the number
migrating through the Matrigel layer was detectable when D2 was added
to the assay. These data indicate that inhibiting uPAR's interaction
with LRP and preventing endocytosis of uPAR significantly reduces the
ability of HT1080 cells to invade and to migrate through extracellular
matrix.
|
| |
DISCUSSION |
|---|
|
|
|---|
It has been established that LRP mediates the clearance of
uPA:PAI-1 from the extracellular environment and that this process is
accompanied by internalization of uPAR (Conese et al.,
1995
), but the clearance mechanism and the intracellular trafficking itinerary of uPAR have remained unknown. In this article we
investigated the nature of the interaction between uPAR and LRP during
clearance of uPA:PAI-1 and their endocytic trafficking. We have shown
that in HT1080 cells, uPAR directly interacts with LRP in the presence of uPA:PAI-1 and that LRP and occupied uPAR form stable complexes that
are cointernalized into EE via clathrin-coated vesicles. We have
further demonstrated that blocking the interaction between the two
receptors results in decreased clearance of uPA:PAI-1 and decreased
plasmin generation at the cell surface and significantly reduces the
ability of the cells to migrate through extracellular matrix in a
standard cell invasion assay.
Our immunofluorescence results indicate that at steady-state LRP
and uPAR are localized in different microdomains of the PM. LRP, like
other members of the LDL receptor gene family, is concentrated in
clathrin-coated pits, whereas uPAR is not associated with either clathrin-coated vesicles or caveolae because it did not colocalize with
either caveolin or with AP-2, markers for caveolae and clathrin-coated pits, respectively (Brodsky, 1997
). The latter finding is in keeping with previous reports indicating that at steady-state uPAR as well as
other GPI-anchored proteins are rather broadly distributed at the cell
surface (Conese et al., 1995
; Maxfield and Mayor, 1997
;
Nykjaer et al., 1997
). However, we found that when cells are
incubated in the presence of uPA:PAI, which binds to uPAR, uPAR forms a
complex with LRP and moves into clathrin-coated pits. That binding is
direct and occurs at the D3 domain of uPAR was suggested by
cross-linking experiments and the fact that addition of recombinant D3
completely blocked both the binding and internalization of occupied
uPAR. This was confirmed by demonstrating that recombinant uPAR binds
to affinity-purified LRP. The demonstration of direct interaction
between uPAR and LRP is a novel finding, because it has been assumed or
implied that uPA-PAI-1 bridges the two receptors and bridging is
sufficient for endocytosis of the complexes (Andreasen et
al., 1994
). There has been no previous work showing a requirement for direct interaction between uPAR and LRP.
It has been shown previously (Behrendt et al., 1991
) that
uPAR is composed of three homologous domains (designated D1, D2, and D3
from the N terminus) of which D1 contains the ligand-binding domain.
Currently, little is known about the physiological functions of D2 and
D3. However, it has been hypothesized that they might increase the
specificity of uPAR for its ligand and facilitate uPAR interaction with
adhesion receptors at the sites of focal contacts (Dear and Medcalf,
1998
). Our findings demonstrate D3 contains a binding site for LRP and
provide novel insights into the function of D3.
We also established that when occupied by uPA:PAI-1 the GPI-anchored
protein uPAR is internalized into EE via clathrin-coated vesicles,
because internalization does not occur when clathrin-mediated endocytosis is blocked by K+ depletion.
Furthermore, uPAR remains associated with LRP during internalization to
EE even after dissociation of uPA:PAI-1 as demonstrated by our
immunoprecipitation analysis on immunoisolated EE. LRP is known to
internalize ligands through a clathrin-dependent pathway mediated by
the NPXY motifs in its cytoplasmic tail, whereas GPI-anchored proteins
such as uPAR lack this motif and are usually assumed to be internalized
via caveolae (Lisanti et al., 1993
; Anderson, 1998
). To our
knowledge, this is the first demonstration of a GPI-anchored protein
piggybacking with another receptor to be internalized via
clathrin-coated vesicles. Indirect evidence suggests that the same
might apply to uPAR and certain integrins (Memmo and
McKeown-Longo, 1998
; Simon et al., 2000
) and to prions, which have been postulated to interact with unknown transmembrane receptors (Shyng et al., 1994
).
Taken together, our results provide evidence for the model of uPA:PAI-1
clearance and uPAR internalization shown in Figure 10. According to this model, formation
of uPA:PAI-1 complexes on uPAR bridges occupied uPAR and LRP at the
cell surface, promotes relocation of occupied uPAR into clathrin-coated
pits, and initiates binding of LRP to the D3 domain of uPAR. This
results in generation of a quaternary complex, uPA:PAI-1/uPAR:LRP,
which is then internalized into EE via clathrin-coated vesicles.
uPA:PAI-1 is released from the receptors in EE and traffics through
late endosomes to lysosomes for degradation (Cubellis et
al., 1990
). Unoccupied uPAR (Nykjaer et al., 1997
) and
LRP recycle to the cell surface. Unoccupied uPAR is available for
binding and activation of pro-uPA, which catalyzes the generation of
plasmin, promoting degradation of extracellular matrix and cell
invasion. When binding of occupied uPAR to LRP is prevented (i.e., in
the presence of recombinant D3), uPA:PAI-1 is still capable of bridging
the two receptors and uPAR redistributes into clathrin-coated pits.
However, internalization of occupied uPAR is prevented, leading to
accumulation of occupied uPAR in clathrin-coated pits on the PM.
Accumulation of redistributed uPAR occupied by inactive uPA at the cell
surface decreases plasmin generation and degradation and invasion of
extracellular matrix.
|
Because activation of secreted pro-uPA requires its binding to
cell surface uPAR (Ellis et al., 1989
; Stephens et
al., 1989
) and unoccupied uPAR constitutes the sole binding and
activation site for pro-uPA at the cell surface (Vassalli et
al., 1985
), it follows that the number of unoccupied uPAR at the
cell surface is a limiting factor in uPA activation and activity.
The net effect of the interaction of between occupied uPAR and
LRP is to remove uPAR with inactive protease (uPA) activity from the
cell surface and replace it with unoccupied uPAR capable of binding
pro-uPA and initiating a new cycle of plasminogen activation. The
importance of LRP in regeneration of cell surface protease activity and
cell migration has previously been demonstrated by the finding that RAP
and anti-LRP antibody impair the regeneration of unoccupied uPAR and
decrease uPA activity of human trophoblast cells (Zhang et
al., 1998
). Moreover, it was reported that LRP-deficient cultured
fibroblasts (Weaver et al., 1997
) and cells in which LRP
expression has been down-regulated by tumor-promoting phorbol esters
(Picone et al., 1989
) have increased amounts of uPAR on their surfaces compared with normal or untreated cells (Picone et
al., 1989
; Weaver et al., 1997
). Our data validate
the unique role of LRP in regulation of extracellular plasminogen
activation and further demonstrate that uPAR binding to LRP is a
mandatory step in the internalization of these receptors and in the
regeneration of unoccupied uPAR.
| |
ACKNOWLEDGMENTS |
|---|
We thank Ileana Popa for preparation of activated
2M. This
work was supported by a Department of Defense Breast Cancer Research Program Grant DAMD-96-1-6317 to M.G.F., Fellowship DAMD17-96-1-6318 to
R.-P.C., and a Peter Lippincola Fellowship to T.K.
| |
FOOTNOTES |
|---|
Corresponding author. E-mail address:
rpczekay{at}scripps.edu.
| |
ABBREVIATIONS |
|---|
Abbreviations used:
2M,
2-macroglobulin;
D2, domain 2 of
uPAR;
D3, domain 3 of uPAR;
EE, early endosomes;
LDL, low density
lipoprotein;
LRP, LDL receptor-related protein;
PAI-1, plasminogen
activator inhibitor type-1;
PM, plasma membrane;
Tf, transferrin;
uPA, urokinase-type plasminogen activator;
uPAR, uPA receptor.
| |
REFERENCES |
|---|
|
|
|---|
v
5 integrin functions as an endocytic receptor for vitronectin.
J. Cell Sci.
111, 425-433[Abstract].
2-macroglobulin receptor as an approximately 440-kDa single chain protein.
J. Biol. Chem.
264, 15574-15577This article has been cited by other articles:
![]() |
B. S. Pedroja, L. E. Kang, A. O. Imas, P. Carmeliet, and A. M. Bernstein Plasminogen Activator Inhibitor-1 Regulates Integrin {alpha}v{beta}3 Expression and Autocrine Transforming Growth Factor {beta} Signaling J. Biol. Chem., July 31, 2009; 284(31): 20708 - 20717. [Abstract] [Full Text] [PDF] |
||||
![]() |
V. D'mello, S. Singh, Y. Wu, and R. B. Birge The Urokinase Plasminogen Activator Receptor Promotes Efferocytosis of Apoptotic Cells J. Biol. Chem., June 19, 2009; 284(25): 17030 - 17038. [Abstract] [Full Text] [PDF] |
||||
![]() |
A. P. Mazar Urokinase Plasminogen Activator Receptor Choreographs Multiple Ligand Interactions: Implications for Tumor Progression and Therapy Clin. Cancer Res., September 15, 2008; 14(18): 5649 - 5655. [Abstract] [Full Text] [PDF] |
||||
![]() |
H. W. Smith, P. Marra, and C. J. Marshall uPAR promotes formation of the p130Cas-Crk complex to activate Rac through DOCK180 J. Cell Biol., August 25, 2008; 182(4): 777 - 790. [Abstract] [Full Text] [PDF] |
||||
![]() |
Y. Liu, D. J. Cao, I. M. Sainz, Y.-L. Guo, and R. W. Colman The inhibitory effect of HKa in endothelial cell tube formation is mediated by disrupting the uPA-uPAR complex and inhibiting its signaling and internalization Am J Physiol Cell Physiol, July 1, 2008; 295(1): C257 - C267. [Abstract] [Full Text] [PDF] |
||||
![]() |
S. Dedieu, B. Langlois, J. Devy, B. Sid, P. Henriet, H. Sartelet, G. Bellon, H. Emonard, and L. Martiny LRP-1 Silencing Prevents Malignant Cell Invasion despite Increased Pericellular Proteolytic Activities Mol. Cell. Biol., May 1, 2008; 28(9): 2980 - 2995. [Abstract] [Full Text] [PDF] |
||||
![]() |
R. Linden, V. R. Martins, M. A. M. Prado, M. Cammarota, I. Izquierdo, and R. R. Brentani Physiology of the Prion Protein Physiol Rev, April 1, 2008; 88(2): 673 - 728. [Abstract] [Full Text] [PDF] |
||||
![]() |
R. E. Griffiths, K. J. Heesom, and D. J. Anstee Normal prion protein trafficking in cultured human erythroblasts Blood, December 15, 2007; 110(13): 4518 - 4525. [Abstract] [Full Text] [PDF] |
||||
![]() |
A. M. Bernstein, S. S. Twining, D. J. Warejcka, E. Tall, and S. K. Masur Urokinase Receptor Cleavage: A Crucial Step in Fibroblast-to-Myofibroblast Differentiation Mol. Biol. Cell, July 1, 2007; 18(7): 2716 - 2727. [Abstract] [Full Text] [PDF] |
||||
![]() |
S. Akkawi, T. Nassar, M. Tarshis, D. B. Cines, and A. A.-R. Higazi LRP and {alpha}vbeta3 mediate tPA activation of smooth muscle cells Am J Physiol Heart Circ Physiol, September 1, 2006; 291(3): H1351 - H1359. [Abstract] [Full Text] [PDF] |
||||
![]() |
M. Stefanidakis and E. Koivunen Cell-surface association between matrix metalloproteinases and integrins: role of the complexes in leukocyte migration and cancer progression Blood, September 1, 2006; 108(5): 1441 - 1450. [Abstract] [Full Text] [PDF] |
||||
![]() |
D. Croucher, D. N. Saunders, and M. Ranson The Urokinase/PAI-2 Complex: A NEW HIGH AFFINITY LIGAND FOR THE ENDOCYTOSIS RECEPTOR LOW DENSITY LIPOPROTEIN RECEPTOR-RELATED PROTEIN J. Biol. Chem., April 14, 2006; 281(15): 10206 - 10213. [Abstract] [Full Text] [PDF] |
||||
![]() |
E. Monaghan-Benson and P. J. McKeown-Longo Urokinase-type Plasminogen Activator Receptor Regulates a Novel Pathway of Fibronectin Matrix Assembly Requiring Src-dependent Transactivation of Epidermal Growth Factor Receptor J. Biol. Chem., April 7, 2006; 281(14): 9450 - 9459. [Abstract] [Full Text] [PDF] |
||||
![]() |
R. Bass, F. Werner, E. Odintsova, T. Sugiura, F. Berditchevski, and V. Ellis Regulation of Urokinase Receptor Proteolytic Function by the Tetraspanin CD82 J. Biol. Chem., April 15, 2005; 280(15): 14811 - 14818. [Abstract] [Full Text] [PDF] |
||||
![]() |
D. Gveric, B. M. Herrera, and M. L. Cuzner tPA Receptors and the Fibrinolytic Response in Multiple Sclerosis Lesions Am. J. Pathol., April 1, 2005; 166(4): 1143 - 1151. [Abstract] [Full Text] [PDF] |
||||
![]() |
V. Llorente-Cortes and L. Badimon LDL Receptor-Related Protein and the Vascular Wall: Implications for Atherothrombosis Arterioscler Thromb Vasc Biol, March 1, 2005; 25(3): 497 - 504. [Abstract] [Full Text] [PDF] |
||||
![]() |
P. P. E. M. Spijkers, P. da Costa Martins, E. Westein, C. G. Gahmberg, J. J. Zwaginga, and P. J. Lenting LDL-receptor-related protein regulates {beta}2-integrin-mediated leukocyte adhesion Blood, January 1, 2005; 105(1): 170 - 177. [Abstract] [Full Text] [PDF] |
||||
![]() |
H. Emonard, G. Bellon, L. Troeberg, A. Berton, A. Robinet, P. Henriet, E. Marbaix, K. Kirkegaard, L. Patthy, Y. Eeckhout, et al. Low Density Lipoprotein Receptor-related Protein Mediates Endocytic Clearance of Pro-MMP-2{middle dot}TIMP-2 Complex through a Thrombospondin-independent Mechanism J. Biol. Chem., December 24, 2004; 279(52): 54944 - 54951. [Abstract] [Full Text] [PDF] |
||||
![]() |
R.-P. Czekay and D. J. Loskutoff Unexpected Role of Plasminogen Activator Inhibitor 1 in Cell Adhesion and Detachment Exp Biol Med, December 1, 2004; 229(11): 1090 - 1096. [Abstract] [Full Text] [PDF] |
||||
![]() |
A. M. Bernstein, R. S. Greenberg, L. Taliana, and S. K. Masur Urokinase Anchors uPAR to the Actin Cytoskeleton Invest. Ophthalmol. Vis. Sci., September 1, 2004; 45(9): 2967 - 2977. [Abstract] [Full Text] [PDF] |
||||
![]() |
A. Schweinitz, T. Steinmetzer, I. J. Banke, M. J. E. Arlt, A. Sturzebecher, O. Schuster, A. Geissler, H. Giersiefen, E. Zeslawska, U. Jacob, et al. Design of Novel and Selective Inhibitors of Urokinase-type Plasminogen Activator with Improved Pharmacokinetic Properties for Use as Antimetastatic Agents J. Biol. Chem., August 6, 2004; 279(32): 33613 - 33622. [Abstract] [Full Text] [PDF] |
||||
![]() |
G. Zhang, X. Cai, J. M. Lopez-Guisa, S. J. Collins, and A. A. Eddy Mitogenic Signaling of Urokinase Receptor-Deficient Kidney Fibroblasts: Actions of an Alternative Urokinase Receptor and LDL Receptor-Related Protein J. Am. Soc. Nephrol., August 1, 2004; 15(8): 2090 - 2102. [Abstract] [Full Text] [PDF] |
||||
![]() |
B. Degryse, J. G. Neels, R.-P. Czekay, K. Aertgeerts, Y.-i. Kamikubo, and D. J. Loskutoff The Low Density Lipoprotein Receptor-related Protein Is a Motogenic Receptor for Plasminogen Activator Inhibitor-1 J. Biol. Chem., May 21, 2004; 279(21): 22595 - 22604. [Abstract] [Full Text] [PDF] |
||||
![]() |
Y. Zhu, H. Bujo, H. Yamazaki, K. Ohwaki, M. Jiang, S. Hirayama, T. Kanaki, M. Shibasaki, K. Takahashi, W. J. Schneider, et al. LR11, an LDL Receptor Gene Family Member, Is a Novel Regulator of Smooth Muscle Cell Migration Circ. Res., April 2, 2004; 94(6): 752 - 758. [Abstract] [Full Text] [PDF] |
||||
![]() |
Y. C. Shin and W. R. Folk Formation of Polyomavirus-Like Particles with Different VP1 Molecules That Bind the Urokinase Plasminogen Activator Receptor J. Virol., November 1, 2003; 77(21): 11491 - 11498. [Abstract] [Full Text] [PDF] |
||||
![]() |
Y. Zhu and D. Y. Hui Apolipoprotein E Binding to Low Density Lipoprotein Receptor-related Protein-1 Inhibits Cell Migration via Activation of cAMP-dependent Protein Kinase A J. Biol. Chem., September 19, 2003; 278(38): 36257 - 36263. [Abstract] [Full Text] [PDF] |
||||
![]() |
M. Demeule, Y. Bertrand, J. Michaud-Levesque, J. Jodoin, Y. Rolland, R. Gabathuler, and R. Beliveau Regulation of plasminogen activation: a role for melanotransferrin (p97) in cell migration Blood, September 1, 2003; 102(5): 1723 - 1731. [Abstract] [Full Text] [PDF] |
||||
![]() |
L. Snyers, H. Zwickl, and D. Blaas Human Rhinovirus Type 2 Is Internalized by Clathrin-Mediated Endocytosis J. Virol., May 1, 2003; 77(9): 5360 - 5369. [Abstract] [Full Text] [PDF] |
||||
![]() |
G. Zhang, H. Kim, X. Cai, J. M. Lopez-Guisa, P. Carmeliet, and A. A. Eddy Urokinase Receptor Modulates Cellular and Angiogenic Responses in Obstructive Nephropathy J. Am. Soc. Nephrol., May 1, 2003; 14(5): 1234 - 1253. [Abstract] [Full Text] [PDF] |
||||
![]() |
L. C. Wilsie and R. A. Orlando The Low Density Lipoprotein Receptor-related Protein Complexes with Cell Surface Heparan Sulfate Proteoglycans to Regulate Proteoglycan-mediated Lipoprotein Catabolism J. Biol. Chem., April 25, 2003; 278(18): 15758 - 15764. [Abstract] [Full Text] [PDF] |
||||
![]() |
R.-P. Czekay, K. Aertgeerts, S. A. Curriden, and D. J. Loskutoff Plasminogen activator inhibitor-1 detaches cells from extracellular matrices by inactivating integrins J. Cell Biol., March 3, 2003; 160(5): 781 - 791. [Abstract] [Full Text] [PDF] |
||||
![]() |
Y. Li, J. M. Knisely, W. Lu, L. M. McCormick, J. Wang, J. Henkin, A. L. Schwartz, and G. Bu Low Density Lipoprotein (LDL) Receptor-related Protein 1B Impairs Urokinase Receptor Regeneration on the Cell Surface and Inhibits Cell Migration J. Biol. Chem., October 25, 2002; 277(44): 42366 - 42371. [Abstract] [Full Text] [PDF] |
||||
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||